Literature DB >> 21655907

Lung cancers unrelated to smoking: characterized by single oncogene addiction?

Kenichi Suda1, Kenji Tomizawa, Yasushi Yatabe, Tetsuya Mitsudomi.   

Abstract

Lung cancer is a major cause of cancer-related mortality worldwide. Currently, adenocarcinoma is its most common histological subtype in many countries. In contrast with small cell lung cancer or squamous cell carcinoma, lung adenocarcinoma often arises in never-smokers, especially in East Asian countries, as well as in smokers. Adenocarcinoma in never-smokers is associated with a lower incidence of genetic alterations (i.e., somatic mutations, loss of heterozygosity, and methylation) than in smokers. In addition, most adenocarcinomas in never-smokers harbor one of the proto-oncogene aberrations that occur in a mutually exclusive manner (EGFR mutation, KRAS mutation, HER2 mutations, or ALK translocation). It is of note that the proliferation and survival of lung cancer cells that harbor one of these oncogenic aberrations depend on the signaling from each aberrantly activated oncoprotein (oncogene addiction). Therefore, most adenocarcinomas in never-smokers can be effectively treated by molecularly targeted drugs that inhibit each oncoprotein. Moreover, from a pathological aspect, lung adenocarcinoma in never-smokers is characterized by terminal respiratory unit-type adenocarcinoma and a particular gene expression profile. Finally, epidemiological analyses have identified many candidate causes of lung cancer in never-smokers (genetic, environmental, and hormonal factors). The elucidation of the particular features of lung cancer unrelated to smoking and the development of new therapeutic modalities may reduce the mortality from lung cancers in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21655907     DOI: 10.1007/s10147-011-0262-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  95 in total

1.  Dose effect of smoking on aberrant methylation in non-small cell lung cancers.

Authors:  Shinichi Toyooka; Makoto Suzuki; Toshihide Tsuda; Kiyomi O Toyooka; Riichiroh Maruyama; Kazunori Tsukuda; Yasuro Fukuyama; Toshihiko Iizasa; Takehiko Fujisawa; Nobuyoshi Shimizu; John D Minna; Adi F Gazdar
Journal:  Int J Cancer       Date:  2004-06-20       Impact factor: 7.396

2.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Authors:  Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber
Journal:  Nat Genet       Date:  2005-10-30       Impact factor: 38.330

3.  Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.

Authors:  M Sanchez-Cespedes; S A Ahrendt; S Piantadosi; R Rosell; M Monzo; L Wu; W H Westra; S C Yang; J Jen; D Sidransky
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer.

Authors:  Q Wei; J Gu; L Cheng; M L Bondy; H Jiang; W K Hong; M R Spitz
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

Review 5.  EGFR mutations and the terminal respiratory unit.

Authors:  Yasushi Yatabe
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

6.  Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Ryoichi Onozato; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

7.  Indirect estimates of lung cancer death rates in Italy not attributable to active smoking.

Authors:  F Forastiere; C A Perucci; M Arcà; O Axelson
Journal:  Epidemiology       Date:  1993-11       Impact factor: 4.822

8.  The histopathology of BRAF-V600E-mutated lung adenocarcinoma.

Authors:  Samuel A Yousem; Marina Nikiforova; Yuri Nikiforov
Journal:  Am J Surg Pathol       Date:  2008-09       Impact factor: 6.394

9.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  12 in total

1.  Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

Authors:  Daniel D Karp; Sandra J Lee; Steven M Keller; Gail Shaw Wright; Seena Aisner; Steven Alan Belinsky; David H Johnson; Michael R Johnston; Gary Goodman; Gerald Clamon; Gordon Okawara; Randolph Marks; Eric Frechette; Worta McCaskill-Stevens; Scott M Lippman; John Ruckdeschel; Fadlo R Khuri
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 2.  Current status of research and treatment for non-small cell lung cancer in never-smoking females.

Authors:  Shin Saito; Fernando Espinoza-Mercado; Hui Liu; Naohiro Sata; Xiaojiang Cui; Harmik J Soukiasian
Journal:  Cancer Biol Ther       Date:  2017-05-11       Impact factor: 4.742

3.  Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.

Authors:  Gou Yamamoto; Mari Kikuchi; Shiho Kobayashi; Yoshiko Arai; Kenji Fujiyoshi; Tomokazu Wakatsuki; Miho Kakuta; Yuki Yamane; Yoshihito Iijima; Hideaki Mizutani; Yuki Nakajima; Junko Sudo; Hiroyasu Kinoshita; Futoshi Kurimoto; Hirohiko Akiyama; Hidetaka Uramoto; Hiroshi Sakai; Yoshito Akagi; Kiwamu Akagi
Journal:  Int J Oncol       Date:  2017-03-27       Impact factor: 5.650

4.  CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Authors:  Pierre Saintigny; Erminia Massarelli; Steven Lin; Young-Ho Ahn; Yulong Chen; Sangeeta Goswami; Baruch Erez; Michael S O'Reilly; Diane Liu; J Jack Lee; Li Zhang; Yuan Ping; Carmen Behrens; Luisa M Solis Soto; John V Heymach; Edward S Kim; Roy S Herbst; Scott M Lippman; Ignacio I Wistuba; Waun Ki Hong; Jonathan M Kurie; Ja Seok Koo
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

5.  Evaluation of the 95% limits of agreement of the volumes of 5-year clinically stable solid nodules for the development of a follow-up system for indeterminate solid nodules in CT lung cancer screening.

Authors:  Ryutaro Kakinuma; Yukio Muramatsu; Junta Yamamichi; Shiho Gomi; Estanislao Oubel; Noriyuki Moriyama
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  ALK and NSCLC: Targeted therapy with ALK inhibitors.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  F1000 Med Rep       Date:  2011-11-01

7.  Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.

Authors:  Tao Huang; Xiaoying Chen; Qingxiao Hong; Zaichun Deng; Hongying Ma; Yanfei Xin; Yong Fang; Huadan Ye; Rujie Wang; Cheng Zhang; Meng Ye; Shiwei Duan
Journal:  Sci Rep       Date:  2015-03-10       Impact factor: 4.379

8.  Maspin expression patterns differ in the invasive versus lepidic growth pattern of pulmonary adenocarcinoma.

Authors:  Fulvio Lonardo; Hui Guan; Sijana Dzinic; Shijie Sheng
Journal:  Histopathology       Date:  2014-09-09       Impact factor: 5.087

9.  Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.

Authors:  Katsuaki Sato; Kenichi Suda; Shigeki Shimizu; Kazuko Sakai; Hiroshi Mizuuchi; Kenji Tomizawa; Toshiki Takemoto; Kazuto Nishio; Tetsuya Mitsudomi
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 10.  Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure.

Authors:  Jung Ran Choi; Seong Yong Park; O Kyu Noh; Young Wha Koh; Dae Ryong Kang
Journal:  Ann Occup Environ Med       Date:  2016-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.